U.K. Healthtech Stock News

Shell is in advanced talks to sell its South African fuel retail business, including around 600 service stations, to Abu Dhabi National Oil Company (ADNOC). The potential deal would mark a significant exit from a country where Shell has operated for more than 100 years. The transaction would further reshape Shell's downstream footprint while giving ADNOC an expanded international retail presence. For investors watching LSE:SHEL, this possible sale comes with the shares around £32.745 and a...

Context for Barratt Redrow’s Recent Share Performance Barratt Redrow (LSE:BTRW) has attracted attention after a month return of 4.69% contrasted with a past 3 months total return decline of 29.01%. This has prompted investors to reassess what the current share price reflects. See our latest analysis for Barratt Redrow. While the recent 1 month share price return of 4.69% hints at some stabilisation after a weak patch, the 1 year total shareholder return decline of 36.54% and 5 year total...

LexisNexis Risk Solutions, part of RELX (LSE:REL), announced an integration with Agenium's no-code platform to streamline electronic health record access for life insurers. The partnership focuses on making medical data retrieval faster and less complex for underwriting and risk assessment workflows. The integration is positioned as a step in expanding RELX's digital health data and risk solutions capabilities for enterprise customers. For RELX, a data and analytics group with exposure to...

What BP’s recent performance data suggests for investors BP (LSE:BP.) has drawn fresh attention after recent performance data showed mixed short term moves alongside strong longer term returns, prompting investors to reassess how the shares line up with the company’s current fundamentals. See our latest analysis for BP. At a share price of £5.569, BP’s 27.2% year to date share price return contrasts with recent weaker short term moves, while the 64.1% one year total shareholder return points...

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...

The United Kingdom's stock market has recently faced challenges, with the FTSE 100 index experiencing declines amid weak trade data from China, highlighting global economic interdependencies. In such a climate, investors may find opportunities in penny stocks—an investment area that remains relevant despite its somewhat outdated terminology. By focusing on companies with strong financial health and growth potential, investors can uncover promising opportunities in smaller or less-established...

In April 2026, global markets have been buoyed by positive developments such as the easing of Middle East tensions and strong U.S. earnings reports, leading to record highs in major indices like the Nasdaq Composite and Russell 2000. Amid this optimistic backdrop, small-cap stocks are capturing investor attention due to their potential for growth and value opportunities, especially when insider buying signals confidence in a company's prospects.

As the UK market grapples with global economic uncertainties, notably influenced by China's sluggish recovery and its impact on commodity-linked stocks, investors are keenly observing the performance of major indices like the FTSE 100 and FTSE 250. In such a volatile environment, identifying undervalued stocks can offer opportunities for those seeking potential value investments; Advanced Medical Solutions Group and two other UK companies may currently be trading below their estimated value.

As the FTSE 100 and FTSE 250 indices experience downward pressure due to weak trade data from China, investors are closely monitoring the broader economic implications for UK markets. In this environment of uncertainty, companies with strong insider ownership can be particularly appealing as they often indicate confidence in long-term growth prospects.

The United Kingdom's FTSE 100 index recently faced downward pressure due to weak trade data from China, highlighting the interconnected nature of global markets and their influence on domestic indices. Amidst these fluctuations, investors often look beyond established giants to uncover potential in lesser-known sectors. Penny stocks, while an outdated term, still represent intriguing opportunities for growth within smaller or newer companies. With strong financial health and solid...

GSK (LSE:GSK) has drawn fresh investor attention after recent share price moves, with the stock showing a 1 day return of 1.0% and a month return of 9.9%. See our latest analysis for GSK. That recent £21.44 share price sits on top of a 30 day share price return of 9.9% and a 90 day gain of 18.1%, while the 1 year total shareholder return of 66.9% points to momentum that has been building rather than fading. If GSK’s run has you thinking about where else growth and new drug platforms might...

Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see PPHE Hotel...

It looks like Sabre Insurance Group plc ( LON:SBRE ) is about to go ex-dividend in the next three days. Typically, the...

The annual results for Tesco PLC ( LON:TSCO ) were released last week, making it a good time to revisit its...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

GSK (LSE:GSK) secures approvals for depemokimab from the European Commission and China’s NMPA, adding to existing authorisations in the United States, Japan, and the UK. Depemokimab is described as the first ultra long acting biologic for its indications in respiratory and inflammatory diseases. The company also reports positive phase 1 data for Mo-Rez, an antibody drug conjugate being studied in difficult to treat gynecologic cancers. For readers following large pharma, GSK (LSE:GSK)...

If you are wondering whether Shell’s current share price reflects its real worth, you are not alone. This article is designed to help you make sense of that question. The stock recently closed at £31.96, with returns of 15.8% year to date and 36.3% over the last year, even though the past 7 and 30 days showed declines of 6.6% and 7.7%. Recent headlines around Shell have focused on its position within the global energy sector and how its capital allocation decisions and portfolio mix are...

Looking at Diploma PLC's ( LON:DPLM ) insider transactions over the last year, we can see that insiders were net...

We wouldn't blame Costain Group PLC ( LON:COST ) shareholders if they were a little worried about the fact that Helen...

What Lloyds Banking Group stock’s recent move means for investors Lloyds Banking Group (LSE:LLOY) has attracted fresh attention after a solid run in recent trading, with the share price up about 2.2% over the past day and roughly 4.2% over the past week. See our latest analysis for Lloyds Banking Group. That recent 1-day share price return of 2.2% and 7-day return of 4.2% come on top of a 30-day share price return of 8.9% and a very strong 1-year total shareholder return of 55.5%, which...

If you are wondering whether RELX is attractively priced or running ahead of itself, this breakdown will help you see how the current share price lines up against a range of valuation checks. The stock last closed at £27.20, with recent returns of 10.3% over 7 days and 6.0% over 30 days, while the year to date return of an 8.8% decline and the 1 year return of a 29.8% decline tell a different story over longer periods. These mixed returns sit against a backdrop of ongoing interest in...

Wondering if AstraZeneca shares still offer value after a strong run, or if the current price already reflects the story you are buying into? The stock last closed at £148.62, with returns of 3.2% over 30 days, 9.3% year to date, 49.4% over 1 year, 31.4% over 3 years, and 115.2% over 5 years. Over the last 7 days, the return was a 2.7% decline. Recent headlines have continued to focus on AstraZeneca's role as a major global pharmaceuticals player and its broad drug portfolio. This keeps...

If you are looking at Unilever and wondering whether the current share price reflects its true worth, the next sections will focus squarely on what you are paying versus what you may be getting. After a recent close at £42.12, the stock has seen returns of a 2.2% decline over 7 days, a 13.7% decline over 30 days, a 12.7% decline year to date, and a 15.3% decline over the past year. This naturally raises questions about whether the risk and return trade off has shifted. Recent headlines...

If you are wondering whether Barclays still represents good value after a strong run, or if most of the upside is already reflected in the share price, this article explains what the market is currently implying about the stock. Barclays has returned 1.0% over the last 7 days and 11.1% over the last 30 days, while year to date the stock is down 8.7% and the 1 year return sits at 61.0%. This compares to a very large 3 year and 5 year return profile. Recent headlines about Barclays have...